Pembrolizumab plus Chemotherapie als Erstlinientherapie beim fortgeschrittenen Ösophaguskarzinom (KEYNOTE-590)Pembrolizumab plus chemotherapy as first-line treatment in advanced oesophageal cancer (KEYNOTE-590)

被引：0
|
作者：
Milan Hartmann
Thomas Zander
Hakan Alakus
机构：
[1] Universitätsklinikum Köln (AöR),Klinik und Poliklinik für Allgemein‑, Viszeral‑, Tumor
[2] Universitätsklinikum Köln, und Transplantationschirurgie
来源：
Der Onkologe | 2022年 / 28卷 / 5期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：436 / 437
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab plus Chemotherapy as First-Line Treatment in advanced Oesophageal Cancer (KEYNOTE-590)
    Hartmann, Milan
    Zander, Thomas
    Alakus, Hakan
    ONKOLOGE, 2022, 28 (05): : 436 - 437
  • [2] Pembrolizumab and Chemotherapy Combination as a First-line Treatment in Patients with advanced Oesophageal Cancer (KEYNOTE-590)
    Hartmann, Milan
    Zander, Thomas
    Alakus, Hakan
    ONKOLOGIE, 2022, 28 (05): : 436 - 437
  • [3] First-line pembrolizumab plus chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
    Kojima, Takashi
    Hara, Hiroki
    Tsuji, Akihito
    Yasui, Hisateru
    Muro, Kei
    Satoh, Taroh
    Ogata, Takashi
    Ishihara, Ryu
    Goto, Masahiro
    Baba, Hideo
    Nishina, Tomohiro
    Han, Shirong
    Sakata, Tomoko
    Yatsuzuka, Naoyoshi
    Doi, Toshihiko
    Kato, Ken
    ESOPHAGUS, 2022, 19 (04) : 683 - 692
  • [4] KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
    Kato, Ken
    Shah, Manish A.
    Enzinger, Peter
    Bennouna, Jaafar
    Shen, Lin
    Adenis, Antoine
    Sun, Jong-Mu
    Cho, Byoung Chul
    Ozguroglu, Mustafa
    Kojima, Takashi
    Kostorov, Vladimir
    Hierro, Cinta
    Zhu, Ying
    McLean, Lee Anne
    Shah, Sukrut
    Doi, Toshihiko
    FUTURE ONCOLOGY, 2019, 15 (10) : 1057 - 1066
  • [5] First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
    Takashi Kojima
    Hiroki Hara
    Akihito Tsuji
    Hisateru Yasui
    Kei Muro
    Taroh Satoh
    Takashi Ogata
    Ryu Ishihara
    Masahiro Goto
    Hideo Baba
    Tomohiro Nishina
    Shirong Han
    Tomoko Sakata
    Naoyoshi Yatsuzuka
    Toshihiko Doi
    Ken Kato
    Esophagus, 2022, 19 : 683 - 692
  • [6] Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
    Kato, K.
    Sun, J-M.
    Shah, M. A.
    Enzinger, P. C.
    Adenis, A.
    Doi, T.
    Kojima, T.
    Metges, J-P.
    Li, Z.
    Kim, S-B.
    Cho, B. C. Chul
    Mansoor, W.
    Li, S-H.
    Sunpaweravong, P.
    Maqueda, M. A.
    Goekkurt, E.
    Liu, Q.
    Shah, S.
    Bhagia, P.
    Shen, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S1192 - S1193
  • [7] Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
    Sun, Jong-Mu
    Shen, Lin
    Shah, Manish A.
    Enzinger, Peter
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Metges, Jean-Philippe
    Li, Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chul
    Mansoor, Wasat
    Li, Shau-Hsuan
    Sunpaweravong, Patrapim
    Maqueda, Maria Alsina
    Goekkurt, Eray
    Hara, Hiroki
    Antunes, Luis
    Fountzilas, Christos
    Tsuji, Akihito
    Oliden, Victor Castro
    Liu, Qi
    Shah, Sukrut
    Bhagia, Pooja
    Kato, Ken
    LANCET, 2021, 398 (10302): : 759 - 771
  • [8] Q-TWiST analysis for pembrolizumab plus chemotherapy versus chemotherapy as first-line treatment for patients with advanced esophageal cancer in the KEYNOTE-590 study
    Diez Garcia, M.
    Shah, S.
    Joo, S.
    Valderrama, A.
    Zhang, S.
    Zhang, Y.
    Enzinger, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S348 - S348
  • [9] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
    Shiu, Kai-Keen
    Rivera, Fernando
    Medley, Louise C.
    Aghmesheh, Morteza
    Dunne, Richard Francis
    Roy, Rajarshi
    Wyrwicz, Lucjan S.
    Larson, Timothy
    Metges, Jean-Philippe
    Mansoor, Wasat
    Goekkurt, Eray
    Moreira Antunes, Luiz Carlos
    Castro Oliden, Victor
    Jensen, Erin
    Shah, Sukrut
    Bordia, Sonal
    Bhagia, Pooja
    Lowery, Maeve Aine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 345 - 345
  • [10] KEYNOTE-590: randomized, phase 3 study of chemotherapy plus pembrolizumab vs chemotherapy plus placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer
    Kato, Ken
    Shah, Manish
    Enzinger, Peter
    Bennouna, Jaafar
    Shen, Lin
    Adenis, Antoine
    Zhu, Ying
    Bhagia, Pooja
    Koshiji, Minori
    Doi, Toshihiko
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
12345